Accelerating Typhoid Conjugate Vaccine Introduction: What Can Be Learned From Prior New Vaccine Introduction Initiatives?
The health consequences of typhoid, including increasing prevalence of drug-resistant strains, can stress healthcare systems. While vaccination is one of the most successful and cost-effective health interventions, vaccine introduction can take years and require considerable effort. The Typhoid Vaccine Acceleration Consortium (TyVAC) employs an integrated, proactive approach to accelerate the introduction of a new typhoid conjugate vaccine to reduce the burden of typhoid in countries eligible for support from Gavi, the Vaccine Alliance. TyVAC and its partners are executing a plan, informed by prior successful vaccine introductions, and tailored to the nuances of typhoid disease and the typhoid conjugate vaccine. The iterative process detailed herein summarizes the strategy and experience gained from the first 2 years of the project.
['Jamka|Leslie P|LP|', 'Simiyu|Kenneth W|KW|', 'Bentsi-Enchill|Adwoa D|AD|', 'Mwisongo|Aziza J|AJ|', 'Matzger|Helen|H|', 'Marfin|Anthony A|AA|', 'Pollard|Andrew J|AJ|', 'Neuzil|Kathleen M|KM|']
D000349:Africa D001208:Asia D014943:Global Health D006801:Humans D017589:Immunization Programs D014435:Typhoid Fever D014436:Typhoid-Paratyphoid Vaccines D014611:Vaccination D018074:Vaccines, Conjugate D014944:World Health Organization
typhoid conjugate vaccine introduction TyVAC Africa Asia